1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1630
  5. Art Unit 1633
  6. Examiner Abuzeineh

Examiner Abuzeineh Hanan I

1633-ABUZEINEH-HANAN-I

Employment Information

Art Unit:1633 — Drug, bio-affecting and body treating compositions
Group:1630 — Stem cells and cell culture and Nucleic Acid related therapy
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
800 — Multicellular living organisms and unmodified parts thereof and related processes
Phone:(571) 272-9596
Email:hanan.abuzeineh@uspto.gov
Location:VA 22314
Title:Pat Examnr (Biology)
Service:4 years
Grade:GS-09

Grant Rate and Difficulty Ranking

94
3-Year Grant rate: 15% over 73 cases
Difficulty: Extremely Hard
Difficulty Percentile: 94th

With Examiner Abuzeineh, you have a 15% chance of getting an issued patent by 3 years after the first office action. Examiner Abuzeineh is an extremely hard examiner and in the 94th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Abuzeineh, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1633

Examiner Abuzeineh's grant rate is lower than that of Art Unit 1633 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Abuzeineh 2.4
Art Unit 1633 2.0

Interview Benefit

Grant Rate without Interview

Examiner Abuzeineh has granted 6 of 65 cases without any applicant-requested interviews for a grant rate of 9%.

Grant Rate with Interview

Examiner Abuzeineh has granted 5 of 8 cases with at least one applicant-requested interview for a grant rate of 62%.

Interview Benefit

With Examiner Abuzeineh, conducting an interview increases your chance of getting a patent granted by 589%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18864633 Method For Treatment Of Myotonic Dystrophy Combining Protein Expression And Rna Interference Vector Delivery With Tissue Detargeting Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
18586064 Engineered Nucleases That Target Human And Canine Factor Viii Genes As A Treatment For Hemophilia A Patented View
17480487 Engineered Immune Cells With Micro-Clusters Patented View
18862369 Compositions And Methods For The Treatment Of Her2 Positive Cancer Abandoned View
16839031 System And Method For The Production, Formulation And Use Of Conditioned Media, Cultured Cells And The Factors Included Therein Patented View
18854315 Formulations For Suprachoroidal Administration Such As Formulations With Aggregate Formation Abandoned View
18855287 Cell Conversion Abandoned View
17923475 Prostate Specific Membrane Antigen Binding Fibronectin Type Iii Domains And Cells Comprising The Same Abandoned View
17689071 Genetically Engineered T Cells With Ptpn2 Knockout Have Improved Functionality And Anti-Tumor Activity Patented View
18865045 Enhancing The Activity Of Cellular Therapies In The Tumor Microenvironment Abandoned View
18864119 Erythroparvovirus With A Modified Genome For Gene Therapy Abandoned View
17440493 Type Vii Crispr Proteins And Systems Patented View
18864430 Improved Cell Therapies Abandoned View
16494252 Compositions And Methods Of Chromosomal Silencing Patented View
18857595 Immortalized Cells For Production Of Bioproducts, Methods Of Producing Bioproducts With An Immortalized Cell, And Methods Of Making Immortalized Cells For Production Of Bioproducts Abandoned View
18856534 Gene Therapy For Treating An Ocular Disease Abandoned View
17275292 Pharmaceutical Combinations For Treating Tumor Comprising Anti-Cd19 Antibody And Natural Killer Cell Patented View
18855606 Capsids For Plakophillin-2 Gene Therapy Abandoned View
16476323 Three-Dimensional Tumor Models, Methods Of Manufacturing Same And Uses Thereof Patented View
17440136 A2/ny-Eso-1 Specific T Cell Receptors And Uses Thereof Patented View
17776537 Tmem59 Protein Dimer Or Chimeric Expression Receptor Improving T Cell Function Abandoned View
17625740 Dimethylarsinous Acid-Induced Malignantly Transformed Cell Line Of Human Keratinocytes And Use Thereof Patented View
18839119 Crispr/spcas9 Variant And Methods For Enhanced Correction Of Duchenne Muscular Dystrophy Mutations Abandoned View
18847011 Use Of Antigen Presenting Cells To Enhance Car-T Cell Therapy Abandoned View
17414410 Lubricin-Localized Cartilage-Like Tissue, Method For Producing Same And Composition Comprising Same For Treating Articular Cartilage Damage Patented View
16927924 System And Methods Relating To Chimeric Autoantibody Receptors Patented View
16649417 Method For Producing Natural Killer Cell And Use Thereof Patented View
16727647 Diet Controlled Expression Of A Nucleic Acid Encoding A Pro-Apoptotic Protein Patented View
18839155 Chimeric Lung Tropic Aav Capsids Abandoned View
18839157 Chimeric Neurotropic Aav Capsids Abandoned View
19250908 Therapeutic Circular Dna Forms Abandoned View
18835868 Treatment Of Liver Cancers By Disrupting The Beta-Catenin/tcf-4 Binding Site Located Upstreatm Of Meg3 In The Dlk1/dio3 Locus Abandoned View
18864130 Erythroparvovirus Compositions And Methods For Gene Therapy Abandoned View
19239389 Bidirectional Chef1 Vectors Abandoned View
18136660 Inducible Promoters Patented View
17770158 Compositions And Methods For Treating Cancer Abandoned View
15929408 Targeting Peptide To Deliver A Compound To Oocytes Patented View
18688688 Aav Capsid Compositions And Methods For Delivery Abandoned View
17205432 Cell Structure Body, Producing Method For Cell Structure Body, Cell Culturing Method, And Micro Flow Path Abandoned View
17597744 Culture Method And Culture Vessel Abandoned View
17602652 Flt3-Specific Chimeric Antigen Receptors And Methods Of Using The Same Abandoned View
17587138 Methods For Transducing Immune Cells Patented View
16394747 Compositions And Methods For Modulating Th-17 And Th-1 Cell Balance Abandoned View
18577221 Gpc3 T Cell-Antigen Couplers And Uses Thereof Abandoned View
18697587 Treatment Of Hereditary Angioedema With Aav Gene Therapy Vectors And Therapeutic Formulations Abandoned View
18716217 P329g Antibody Targeting Bcma, Combination Of Same With Chimeric Antigen Receptor Cell, And Use Thereof Abandoned View
19093913 Cell-Type Specific Regulatory Elements For Photoreceptors Abandoned View
18011624 Polynucleotide Abandoned View
17593087 Humanized Anti-Dll3 Chimeric Antigen Receptors And Uses Thereof Abandoned View
16960370 Bidirectional Chef1 Vectors Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.